Related Experiment Video

Updated: May 4, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K

The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance

Christiane R Maroun1, Tracey Rowlands1

  • 1Mirati Therapeutics, 7150 Frederick-Banting, Suite 200, Montreal, Quebec H4S 2A1, Canada.

Pharmacology & Therapeutics
|January 4, 2014
PubMed

Insights

The Met receptor tyrosine kinase (RTK) is a key target in cancer therapy. Targeting Met or its ligand HGF shows promise for improving patient survival through novel therapeutics and biomarkers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The Met receptor tyrosine kinase (RTK) and its ligand, hepatocyte growth factor (HGF), are crucial in cancer progression, influencing cell proliferation, invasion, angiogenesis, and cancer stem cell regulation.
  • Elevated Met/HGF levels and genetic alterations are linked to poor prognosis in various human cancers.
  • Met signaling crosstalks with other receptor tyrosine kinases (RTKs) like EGFR, HER2, and VEGFR, contributing to resistance against targeted therapies.

Purpose of the Study:

  • To review the therapeutic potential of targeting the Met pathway in oncology.
  • To highlight the prognostic significance of Met expression in diverse cancers.
  • To discuss the role of Met in therapeutic resistance and the development of predictive biomarkers.

Main Methods:

  • Review of preclinical and clinical data on Met and HGF inhibitors (antibodies and small molecules).
  • Analysis of studies investigating the prognostic value of Met expression across multiple cancer types.
  • Examination of clinical trial outcomes related to Met inhibitor efficacy and patient response.

Main Results:

  • Extensive data supports Met/HGF-targeted therapies as viable oncology treatments.
  • Met expression levels are increasingly recognized as determinants of clinical trial outcomes.
  • Met signaling plays a significant role in acquired resistance to other RTK-targeted therapies.

Conclusions:

  • Targeting Met or HGF presents a promising therapeutic strategy for various cancers.
  • Met expression serves as a potential prognostic and predictive biomarker for guiding treatment decisions.
  • Future research focuses on advanced methodologies for developing validated Met-based biomarkers to enhance patient survival in conjunction with targeted therapeutics.
Keywords:
BiomarkerDrug resistanceHGFMetPrecision medicineTargeted therapy

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K